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Antimicrobial Treatment Improves Mycobacterial Survival in
Nonpermissive Growth Conditions
Obolbek Turapov,a Simon J. Waddell,b Bernard Burke,a Sarah Glenn,a Asel A. Sarybaeva,a Griselda Tudo,c* Gilles Labesse,d,e
Danielle I. Young,f Michael Young,f Peter W. Andrew,a Philip D. Butcher,c Martin Cohen-Gonsaud,d,e Galina V. Mukamolovaa
Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdoma; Brighton and Sussex Medical School, University of Sussex,
Brighton, United Kingdomb; Medical Microbiology, Centre for Infection and Immunity, Division of Clinical Sciences, St. George’s University of London, London, United
Kingdomc; Centre de Biochimie Structurale, CNRS UMR 5048, Montpellier, Franced; INSERM U1054, Université Montpellier I et II, Montpellier, Francee; Institute of Biological,
Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, United Kingdomf
Antimicrobials targeting cell wall biosynthesis are generally considered inactive against nonreplicating bacteria. Paradoxically,
we found that under nonpermissive growth conditions, exposure ofMycobacterium bovis BCG bacilli to such antimicrobials
enhanced their survival. We identified a transcriptional regulator, RaaS (for regulator of antimicrobial-assisted survival), en-
coded by bcg1279 (rv1219c) as being responsible for the observed phenomenon. Induction of this transcriptional regulator re-
sulted in reduced expression of specific ATP-dependent efflux pumps and promoted long-term survival of mycobacteria, while
its deletion accelerated bacterial death under nonpermissive growth conditions in vitro and during macrophage or mouse infec-
tion. These findings have implications for the design of antimicrobial drug combination therapies for persistent infectious dis-
eases, such as tuberculosis.
The discovery of antimicrobial drugs was a key advance inmed-ical microbiology and has revolutionized the treatment of in-
fectious diseases. The importance of effective antimicrobial drug
therapy is highlighted by the current challenges of genotypic drug
resistance (1) and phenotypic drug tolerance (2). Antimicrobial
agents may either have no effect on bacterial cells (due to drug
resistance or tolerance), kill bacteria (bactericidal antimicrobials),
inhibit bacterial growth without killing them (bacteriostatic anti-
microbials), or, on very rare occasions, support their growth as a
nutrient or stabilizer of ribosomes in streptomycin-dependent
strains (3, 4). The efficacy of antimicrobials against drug-sensitive
bacteria depends on many factors, such as the ability to activate
starvation responses (5), cell-cell interactions in heterogeneous
populations (6), the host-pathogen interplay (7, 8), and the met-
abolic state of the cells (9–12). Several infectious diseases, includ-
ing tuberculosis, are caused by pathogens with the ability to
survive in low metabolic activity states, which extends and com-
plicates therapeutic drug regimens.
Tuberculosis remains a leading cause of morbidity and mor-
tality worldwide. Frontline treatment for nonresistant strains in-
cludes 6 months of therapy with a combination of four drugs:
rifampin, isoniazid, ethambutol, and pyrazinamide. Isoniazid, a
prodrug activated by catalase, targets the synthesis of mycolic ac-
ids (13). Ethambutol is a bacteriostatic drug that interferes with
the synthesis of arabinogalactan and is included in the standard
regimen primarily to prevent the emergence of drug resistance
(14). Rifampin has a very potent lethal effect on growing and
nongrowing Mycobacterium tuberculosis bacilli (15). Finally, pyr-
azinamide is a prodrug that is converted into pyrazinoic acid
(POA) and is capable of killing nonreplicating cells by inhibiting
trans-translation (16). The potential antimycobacterial drug arse-
nal has been extended recently by the development of several
novel compounds that target cell wall biosynthesis and the respi-
ratory chain (17). In addition, well-known inhibitors of efflux
pumps, such as verapamil and reserpine, are now considered pos-
sible chemotherapeutic agents (8, 18). However, elimination of
persistent or nonreplicating M. tuberculosis bacilli still presents
serious challenges, mainly due to our limited knowledge of the
mechanisms underlying their transition to nongrowing states.M.
tuberculosis is able to survive in vivo and in vitro for years, as evi-
denced by the observation that one-third of the global population
is estimated to be latently infected with this bacterium (19, 20).
Moreover, experimental data suggest thatM. tuberculosis can sur-
vive stasis efficiently and, unlike many other bacteria, retains high
viability through the stationary phase (12) and in chronic infec-
tion models (21, 22). Numerous studies have identified and de-
scribed factors that mediate successful M. tuberculosis survival in
the stationary phase. These factors include enzymes involved in
specific metabolic adaptations, transcriptional regulators, sigma
factors, stress response proteins, and cell wall enzymes (12).
In the present study, we further reveal the complexity of met-
abolic regulation inmycobacteria during their transition to a non-
replicating state. Our data suggest that tight control of efflux
pumps is critical for bacterial survival in nongrowing conditions.
Moreover, we show how certain frontline antimicrobials may in-
fluence this control and actually improve bacterial survival under
nonpermissive growth conditions. These findings offer an alter-
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native strategy for targeting nonreplicating bacilli in vivo, precisely
the bacteria that are most difficult to eliminate with current anti-
microbials (15, 23–25).
MATERIALS AND METHODS
Organisms and media. Mycobacterium bovis BCG Glaxo strain and My-
cobacterium tuberculosis H37Rv were grown in Sauton’s or Middlebrook
7H9 liquid medium (Becton, Dickinson and Company) supplemented
with albumin-dextrose complex. For generation of prolonged stationary
phase, 2 l from a 1-month-old culture was inoculated in 20 ml of sup-
plemented Sauton’s medium (the composition of this medium is de-
scribed in the supplemental material) in 100-ml flasks sealed with Suba-
Seal stoppers (William Freeman Ltd., Barnsley, United Kingdom). The
inoculated flaskswere incubated at 37°Cwithout shaking. Chemicals were
added 30 days after inoculation at the following final concentrations (in
g/ml): ethambutol, 20; isoniazid, 50; cerulenin, 50; streptomycin, 100;
metronidazole, 50; reserpine, 20; verapamil, 20; carbonyl cyanidem-chlo-
rophenylhydrazone (CCCP), 10. Sterile water (or dimethyl sulfoxide
[DMSO]) was added to control cultures. Viability was assayed by estima-
tion of CFU and most probable number (MPN) counts as described pre-
viously (24). Briefly, for CFU counts, 10-l drops of serially diluted bac-
teria were spotted on 7H10 agar; for MPN counts, 50-l aliquots of
serially diluted bacteria were inoculated into 48-well microtiter plates
containing 450l of supplemented Sauton’smediumdilutedwith culture
supernatant obtained from a growingM. bovis BCG culture (optical den-
sity at 580 nm [OD580], 0.8). Bacterial suspensions were passed through a
23-gauge needle to break aggregates. For MPN and CFU counts, 4 to 8
replicates of each dilution were inoculated in supplemented Sauton’s me-
dium or on 7H10 agar plates. The inoculated plates were sealed with
Nescofilm, placed in plastic bags, and incubated at 37°C for 6 weeks with-
out shaking. MPN counts were determined using a published protocol.
MPN counts were calculated with 95% confidence limits by using the
FDA’s procedure (24). Data are presented as the percent survival relative
to that of the stationary-phase culture before treatment (means  stan-
dard errors of the means [SEM], n 3). All experiments were repeated at
least 3 times.
raaS overexpression and deletion. The RaaS-encoding region, in-
cluding 31 bp upstream of the predicted coding sequence, was amplified
from M. tuberculosis H37Rv DNA and cloned into the BamHI and SpeI
sites of the pMind plasmid (26). raaS overexpression was induced by the
addition of 20 ng/ml tetracycline. Overexpression of raaS was confirmed
by quantitative reverse transcription-PCR (qRT-PCR). In-frame 573-bp
raaS deletion mutants of M. tuberculosis H37Rv and M. bovis BCG were
generated by using a homologous recombination approach as described
previously (27). Deletion mutants were confirmed by PCR and sequenc-
ing. To complement the knockout mutants, full-length rv1219c (raaSMtb)
was cloned into SpeI and HpaI sites of an integrating vector, pRBexint, to
ensure constitutive expression from a dnaK promoter (28). All oligonu-
cleotides used in this study are detailed in Table S2 of the supplemental
material.
Transcriptional profiling. Total RNA was isolated from 30-ml ali-
quots fromM. bovis BCG stationary-phase cultures after 24 h of exposure
to the antimicrobial compounds, using the TRIzol method (29) (for de-
tails, see the supplemental material). Microarray data were confirmed by
quantitative RT-PCR.
Purification of recombinant RaaS. The raaS gene was cloned into
NdeI and NheI sites of the pET15-Tev plasmid to generate a 6His-
tagged recombinant protein. Protein expression was induced by isopro-
pylthio--galactoside at a final concentration of 0.2 mM. Recombinant
RaaS was purified by using a HiTrap 1-ml immobilized-metal affinity
high-performance column (Amersham Biosciences). The structural in-
tegrity of the RaaS protein was validated by circular dichroism.
Electrophoretic mobility shift assay. The RaaS upstream region, or
synthetic oligonucleotides covering the upstream region, was used for the
experiments. DNA was mixed with purified RaaS protein in buffer con-
taining 25mMTris (pH 8.0), 50mMNaCl, 0.25mMEDTA. Themixture
was run on a 5% (wt/vol) polyacrylamide gel in 0.25 Tris-borate-EDTA
buffer. Ethidium bromide-stained gels were visualized and the images
captured using the GeneSnap system (Syngene UK). In some experi-
ments, shifted bands were visualized using 32P-radiolabeled double-
stranded oligonucleotides.
Fluorescence anisotropy. The synthetic oligonucleotides, containing
imperfect direct repeats, were covalently labeled with Atto 647N succin-
imidyl ester dye (Invitrogen). Steady-state fluorescence anisotropy bind-
ing titrationswere carried out on aTecan Safire IImicroplate reader, using
a 635-nm light-emitting diode for excitation and amonochromator set at
680 nm (bandwidth, 20 nm) for emission in buffer containing 50 mM
Tris-HCl (pH 8.5) and 150 mM NaCl.
Macrophage infection experiments. The human Mono Mac 6 mac-
rophage-like cell line (30) was infected with M. tuberculosis bacilli at a
multiplicity of infection (MOI) of 5 or 0.1. Infection and MOIs were
confirmed by staining 2% (wt/vol) paraformaldehyde-fixedmacrophages
by using the TB Quick kit (Reactif RAL). For CFU counts, infected mac-
rophages were lysed with 0.006% (wt/vol) SDS at 24, 48, 72, 96, and 120 h
postinfection, serially diluted, and plated on 7H10 plates. Three indepen-
dent experiments were done for each MOI.
Mouse infection experiments. M. bovis BCG Glaxo cells (wild type
[WT], the raaS strain, and the corresponding raaS-complemented
strain, raaScom) were grown in 7H9 supplemented medium to logarith-
mic phase (OD580, 0.4 to 0.6), washed three times with 10% (vol/vol)
glycerol, and flash-frozen in liquid nitrogen. Before infection, defrosted
cells were centrifuged to remove glycerol; the cell pellets were resuspended
in phosphate-buffered saline and passed through a 25-gauge needle 10
times. BALB/c mice (Charles River, United Kingdom) were lightly anes-
thetized with 2.5% (vol/vol) isoflurane over oxygen (1.8 to 2 litersmin1)
and infected intranasally with 1 106 mycobacteria. For each time point,
bacterial loads from 5 separate mice were determined. At 1, 7, 10, 14, 17,
and 21 days postinfection, mice were culled and their lungs and spleens
homogenized in 7H9 medium for determination of CFU counts. Serially
diluted cells were plated on 7H10 agar, and plates were incubated 37°C for
up to 8 weeks.
Statistical analysis. All data are presented as means SEM (n 3).
For statistical analysis of bacterial survival in vitro, an unpaired t test was
employed. Statistically significant differences in bacterial loads in mice
were determined by a one-way analysis of variance (ANOVA). Signifi-
cantly differentially expressed genes were identified by comparing the
results with the knockout mutant to both wild-type and complemented
strain results by using a t test (at a P level of 	0.05, with Benjamini and
Hochbergmultiple testing correction) and a change threshold of2-fold.
Ethics statement. Experiments were carried out in accordance with
the Animals (Scientific Procedures) 1986 protocols and under Home Of-
fice project license number 60/4327. Experiments were approved by the
Research Ethics Committee, University of Leicester, Leicester, United
Kingdom.
Microarray data accession numbers. Fully annotated microarray
data have been deposited in the BG@Sbase database (accession number
E-BUGS-123 [http://bugs.sgul.ac.uk/E-BUGS-123]) and also ArrayEx-
press database (accession number E-BUGS-123).
RESULTS
Antimicrobials enhance bacterial survival under nonpermis-
sive growth conditions. We first compared survival of M. tuber-
culosisH37Rv andM. bovis BCG in prolonged stationary phase in
sealed flasks without shaking.While a reduction in viable bacterial
counts was observed for both organisms, the survival dynamics of
M. tuberculosis andM. bovisBCGpopulations differed (Fig. 1A). A
3-month incubation resulted in a 1,000-fold difference in survival
between M. tuberculosis and M. bovis BCG cultures, confirming
thatM. bovis BCG is attenuated for long-term persistence in vitro
compared to M. tuberculosis (P 	 0.001, t test). To establish
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whether stationary-phase M. bovis BCG populations have a mix-
ture of dying and slowly growing cells, we treated 1-month-oldM.
bovis BCG cultures with antimicrobials with activity against rep-
licating bacteria, targeting cell wall biosynthesis (ethambutol, iso-
niazid, and cerulenin) or inhibiting the translation machinery
(streptomycin). To avoid selection of resistant mutants and en-
sure the presence of active antimicrobials during the prolonged
exposure, we applied very high concentrations of antimicrobials
that greatly exceeded the MICs. The effects of these drugs on cell
viability were followed over a 2-month period. After 24 h of expo-
sure, streptomycin caused marked cell death (2 log10) of the
1-month-old cultures, with cell survival of 0.23% 0.1%. Etham-
butol, isoniazid, or cerulenin had no effect on cell viability (see
Fig. S1 in the supplementalmaterial), indicating that the cells were
probably not actively replicating and not undergoing cell wall syn-
thesis. As described above, a 2-month incubation of drug-free
control cultures resulted in a pronounced loss of viability from ca.
107 cells/ml to ca. 104 cells/ml, while treatment with streptomycin
and metronidazole reduced viable counts to ca. 103 cells/ml (Fig.
1B). In contrast, cultures incubated for 2 months in the continu-
ous presence of antimicrobial compounds affecting cell wall bio-
synthesis still contained substantial numbers of viable cells (106
viable cells/ml). In the case of ethambutol, more than 40% of the
population remained viable, compared with 0.02% in the drug-
free control (Fig. 1B). Interestingly, the posttreatment lag phase
upon resuscitation of growth in fresh drug-free liquid and solid
media was reduced in ethambutol-treated bacilli (20 2 days for
the growth of visible colonies) relative to untreated bacilli (30 4
days), indicating that the treated cells were probably less damaged
during storage and did not require additional time for recovery.
Importantly, survivingM. bovis BCG bacilli remained fully sensi-
tive to the drugs used, with identical MICs for treated and un-
treated cells (see the MIC determinations reported in the supple-
mental material); therefore, emergence of genotypic resistance
may be excluded as a mechanism of bacterial survival in drug-
treated samples.
This antimicrobial-assisted improvement of bacterial survival
in M. bovis BCG cultures was only observed in sealed flasks that
were not shaken. It was highly growth phase dependent, occurring
only after stationary phase had been reached and not during log-
phase growth, indicating the importance of nonpermissive growth
conditions for this persistence phenomenon.We next focused our
efforts on elucidating the mechanisms underlying the observed
survival defect of M. bovis BCG and its improvement by antimi-
crobial treatment.
The predicted transcriptional regulator RaaS is important
for antimicrobial-enhanced survival under nonreplicating con-
ditions.Whole-genome transcriptional profiling of 1-month-old
M. bovis BCG cultures revealed a common signature of differen-
tially expressed genes for ethambutol-, cerulenin-, or isoniazid-
treated bacilli compared with streptomycin-treated or drug-free
bacteria (see Table S1 and Fig. S2 in the supplemental material).
Of particular interest among these genes, bcg_1279c encodes a
predicted transcriptional regulator of unknown function, with or-
thologues inM. tuberculosis (rv1219c) andM. bovis (mb1251c). In
M. bovis BCG Glaxo and Pasteur strain, Bcg_1279c (which we
designated RaaS, for regulator of antimicrobial-assisted survival,
based on the findings described below) only differs in itsM. tuber-
culosis andM. bovis homologues by one amino acid (W113C), due
to a single G-to-C substitution. Both proteins are likely to have
similar roles in these closely related organisms. We reasoned that
the induction of this transcriptional regulator 24 h after treatment
with cell wall-targeting antimicrobials might be responsible for
controlling an adaptive response that enhances the survival of
mycobacteria in extended stationary phase. We cloned and over-
expressed M. tuberculosis raaS (raaSMtb) in M. bovis BCG under
the control of a tetracycline-inducible promoter. Quantitative
RT-PCR confirmed that tetracycline treatment induced raaS ex-
pression 25-fold. Mycobacteria overexpressing raaSMtb survived
better in prolonged stationary phase (Fig. 2A) and recovered
sooner than the empty vector control (see Fig. S3 in the supple-
mental material), highlighting a role for RaaS in long-termmyco-
bacterial viability.
The functional significance of RaaS in antimicrobial-assisted
survival was further explored by constructing an M. bovis BCG
raaS in-frame deletion mutant (raaS), and the corresponding
raaS-complemented strain (raaScom) (Fig. 2B). The raaS mu-
tant did not display any significant defects in the logarithmic
growth phase (see Fig. S4 in the supplemental material), confirm-
ing the previous observation from screening of anM. tuberculosis
H37Rv transposon library that defined raaS as nonessential for
mycobacterial growth in vitro (31). The survival of the raaS
strain was reduced compared to the wild type during a drug-free
extended stationary phase, with only 0.12% and 0.33%, respec-
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FIG 1 Survival of M. bovis BCG in prolonged stationary phase and the effect of antimicrobial treatment. (A) M. bovis BCG and M. tuberculosis were grown in
sealed flasks to stationary phase and were incubated for a further 90 days. (B) One-month-old M. bovis BCG cultures were treated with antimicrobials and
incubated for an additional 2 months before viability was assayed. **, statistically different from untreated control (P	 0.01; n
 5). H2O, water control; Str,
streptomycin; Emb, ethambutol; INH, isoniazid; Cer, cerulenin; MNZ, metronidazole. Mean values of five independent experiments are presented.
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tively, of initial populations recovered (Fig. 2B). The knockout
mutant complemented with wild-type raaS on an integrating vec-
tor, the raaScom strain, survived long-term stationary phase to a
much greater degree, with 41% of the original population able to
produce colonies on solid medium. This phenotype was observed
in the raaS mutant strains complemented either by M. tubercu-
losis or M. bovis BCG versions of raaS (survival values in both
strains did not differ statistically [P 0.1, t test]), confirming that
RaaS from either bacterium is capable of playing the same role.
This dramatic increase in survival (without the addition of drug)
in the complemented strain compared to the wild type is likely to
be due to the overexpression of raaS in the complemented strain,
analogous to the effect observed when raaS was deliberately over-
expressed (Fig. 2A). Quantitative RT-PCR demonstrated that
raaS was indeed 2.6-fold overexpressed in the complemented
strain compared to thewild type. The addition of ethambutol after
1month of incubation was beneficial for the survival of all strains,
with approximately 50% of the original populations of wild-type
and complemented M. bovis BCG bacilli viable after incubation
for a further 2 months (Fig. 2B). Only 8% of the raaS strain
population remained viable. This confirmed that deletion of raaS
limited the ability of mycobacteria to survive after long-term an-
timicrobial exposure and also indicated that additional factors
might be involved in regulation of this pathway.
To investigate whether RaaS plays a role in mycobacterial sur-
vival in vivo, three separate groups of BALB/c mice were infected
with either wild-type M. bovis BCG, the raaS deletion mutant
strain (raaS), or the raaS complemented mutant strain
(raaScom).M. bovis BCG does not replicate in BALB/c mice, and
after several weeks of infection most bacilli are cleared from mu-
rine lungs (32, 33). Therefore, this model may be considered an in
vivo model of bacterial survival under conditions nonpermissive
for growth. Figure 2C shows the fate of M. bovis BCG in mouse
lungs during 3 weeks of infection. A decrease in bacterial numbers
was observed in all strains. However, the deletion mutant strain
was attenuated compared to the wild type and the complemented
mutant strain (P	 0.001, one-way ANOVA). After 3 weeks, there
was a 10-fold difference in bacterial loads of the raaS strain and
the wild type in the lungs (Fig. 2C); complementation of the dele-
tion restored the wild-type phenotype. In murine spleens, BCG
could only be detected at 17 and 21 days because of gradual dis-
semination from the lungs (Fig. 2D). The mutant phenotype in
the spleen was partially restored at 17 days and fully comple-
mented at 21 days. Thus, our data demonstrate that RaaS is func-
tionally significant both in vitro and in vivo.
RaaS acts as a transcription repressor of predicted ATP-de-
pendent efflux pumps. To identify the RaaS regulon, we per-
formed microarray-based whole-genome transcriptional profil-
ing of the raaS mutant strain relative to the complemented
mutant strain and wild-typeM. bovis BCG. Seven genes were sig-
nificantly differentially expressed in theraaSmutant strain com-
pared to either the wild-type or complemented mutant strains
FIG 2 Effects of raaS overexpression or deletion on survival of M. bovis BCG in nonpermissive growth conditions in vitro and in vivo. (A) Strains containing
pMind or pMind-raaS were incubated in tetracycline-supplemented medium for 107 days. **, statistically different survival between pMind-raaS and pMind
(P	 0.01; n
 3). (B) Stationary-phase cultures of wild-type, raaS, and raaScom strains were treated with ethambutol and incubated for a further 2 months.
**, statistically significant enhanced survival compared to drug-free wild-type control (P	 0.01; n
 3). (C and D) Bacterial loads in lungs (C) and spleens (D)
of infected mice. (C) ***, raaS strain loads in lungs at 7 to 21 days were statistically lower than wild-type or raaScom strain loads (P	 0.001). (D) **, raaS
strain loads in spleens were statistically significantly lower (P	 0.01) than wild-type and raaScom strain loads.
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(Table 1). This pairwise comparison controlled for polar effects
thatmight have resulted from the removal of raaS from the knock-
out mutant. As an additional precaution, the sequence of this
region of the genome in the knockout and complemented strains
was confirmed to be identical (other than the deletion of raaS). Of
the putative RaaS regulon (Table 1), one gene (bcg3553, homolo-
gous to rv3489) was repressed in the raaS strain, while 5 genes
(drrC and bcg1278c/bcg1277c/bcg1276c/bcg1275c, corresponding
to rv1218c/rv1217c/rv1216c/rv1215c) were induced. This indicated
that RaaS likely acts as a repressor of drrC (bcg2960), which en-
codes an annotated efflux pump, as well as the cluster of genes
located immediately downstream from itself (Fig. 3A and B).
These genes are predicted to encode ABC transporters (bcg1278c/
bcg1277c) and are associated with integral membrane proteins
(bcg1276c/bcg1275c), suggesting that downregulation of the cellu-
lar export machinery is required for mycobacterial survival under
conditions nonpermissive for growth. Interestingly, only bcg1278c
and raaSwere among the genes differentially expressed inM. bovis
BCG treated with the antimicrobials that improved bacterial sur-
vival compared to the control (see Table S1 in the supplemental
material). Our results strongly suggest that antimicrobial-medi-
ated activation of this transcriptional regulator has a protective
effect in extended stationary phase, by repressing the expression of
putative efflux pumps. In accordance with this conclusion, an
increase in viability, compared to the control was observed in
extended stationary phase after exposure of 1-month-oldM. bovis
BCG cultures to the ABC efflux pump inhibitor reserpine or the
proton ionophore CCCP (Fig. 3C). Verapamil had a very moder-
ate effect on bacterial viability, presumably due to its relatively low
stability in solutions with pH over 6.0 (34).
Identification and characterization of the RaaS DNA bind-
ing site. raaS is the first gene in an operon containing 5 genes
TABLE 1 Genes significantly differentially expressed in the raaS strain versus the WT or raaScom strain, thus defining the putative RaaS regulon
M. bovis BCG
gene
M. tuberculosis
homologue Predicted function
Fold change for raaS strain vs WT or raaScom strain (assay method)
a
Fold change for raaScom
vs WT (qRT-PCR)WT (MA) raaScom (MA) WT (qRT-PCR) raaScom (qRT-PCR)
bcg1278c rv1218c ABC transporter 29.56 46.45 48.9 82.79 1.69
bcg1277c rv1217c ABC transporter 21.14 34.86 33.00 62.95 1.81
bcg1276c rv1216c Methyltransferase 8.13 12.10 13.97 25.37 1.81
bcg1275c rv1215c Peptidase 2.50 3.00 2.15 1.95 1.09
drrC drrC ABC transporter 2.07 2.09 2.00 1.26 1.59
bcg3553 rv3489 Hypothetical protein 2.22 3.45 1.05 1.22 1.15
a Fold change relative to the WT or raaScom strain was determined by microarray (MA) or qRT-PCR.
FIG 3 RaaS binds to its upstream region. (A) Schematic representation of the raaS operon inM. tuberculosis. (B) Intergenic region between raaS and rv1220c,
containing the predicted10 and35 promoter elements (boxed). The RaaS-binding site is shown in red; the predicted raaS start and bcg1280c stop codons are
underlined. (C) Influence of efflux inhibitors on survival of M. bovis BCG in extended stationary phase. ***, ethambutol (Emb)-, reserpine (Res)-, or CCCP-
treated cells survived significantly better (P	 0.001) than drug-free controls.
Turapov et al.
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(Fig. 3A) and is separated by 140 nucleotides from the upstream
gene bcg1280c in M. tuberculosis rv1220c (Fig. 3A and B). The
nucleotide sequence of this intergenic region is identical in M.
bovis BCG and M. tuberculosis. Electrophoretic mobility shift as-
says revealed that RaaSwas able to bind to this region (Fig. 4A). To
identify a binding site, we designed a series of oligonucleotides
covering the entire region between bcg1280c and the first 10 nu-
cleotides of raaS (Fig. 3B) and performed electrophoreticmobility
shift assays (Fig. 4B). We found that only oligonucleotides con-
taining two 12-bp imperfect direct repeats separated by the pre-
dicted raaS10 promoter element were bound by RaaS (Fig. 3B
and 4B). Both repeats were necessary for RaaS binding, as trunca-
tion of the sequence or replacement of three thymidines in one
repeat with adenosines led to complete loss of binding (Fig. 4C).
Each repeat was characterized by the presence of two 5-nucleotide
inverted repeats, and the second repeat included the predicted start
codonof raaS (Fig. 3B). Suchorganizationof theoperonsuggests that
RaaS represses expression of its own gene and other genes in the
operon, supporting our regulon prediction from the transcriptomics
signatures. Moreover, the necessity of both imperfect direct repeats
forRaaSbinding suggests thatRaaS interactswith theDNAsequence,
as shown for transcriptional regulators (35).
The specific binding of RaaS to the identified DNA site was
further confirmed by fluorescence anisotropy. Oligonucleotides
defining the binding site were labeled with Alexa Fluor 488 dye
and mixed with unlabeled RaaS. RaaS exhibited a strong specific
DNA-binding activity with an estimated binding constant of 31
nM 6 nM (Fig. 4D). Thus, RaaS can be classified as an autotran-
scriptional repressor. An autotranscriptional repressor, encoded
by the first gene in an operon, inhibits transcription of itself and
the other genes in the operon. Such an organization ensures a tight
regulation of operon expression, and autotranscriptional repres-
sors are highly conserved in bacteria (36).
RaaS is important for survival in prolonged stationary phase
and during macrophage infection. Finally, we investigated
whether RaaS contributed to persistence ofM. tuberculosis in pro-
longed stationary phase in vitro and duringmacrophage infection.
In our initial experiments, we attempted to study the effect of
ethambutol and reserpine on survival ofM. tuberculosis in station-
ary phase.However, asmentioned above, unlikeM. bovisBCG,M.
tuberculosis retained a relatively high level of viability after 2
months of incubation in stationary phase. Nearly 30%  5% of
bacteria could be recovered from control flasks, while ethambu-
tol- or reserpine-treated cultures contained even higher numbers
of viable mycobacteria, 45% 6% and 67% 10%, respectively.
The differences between control and both treated samples were
statistically different (P	 0.001, t test); however, they were not as
marked as seen in the case ofM. bovis BCG. Further incubation is
likely to have resulted in degradation of drugs; therefore, we were
not able to demonstrate that the drugs had similar effects on M.
tuberculosis as onM. bovisBCG.We therefore investigated the role
of RaaS in survival of untreatedM. tuberculosis for longer periods.
The viability of the M. tuberculosis raaS knockout mutant
FIG 4 Characterization of the RaaS-binding site. (A) Electrophoreticmobility shift assay results. A 174-bpDNA fragment (the raaS upstream region) wasmixed
with proteins. Lanes 1, DNA alone; 2, DNA with RaaS; 3, DNA with bovine serum albumin; 4, DNA with rPASTA protein; M, DNAmarkers. (B) Identification
of the RaaS-binding site. Six pairs of oligonucleotides (Pr6, -7, -8, -14, -15, and -16 [for the sequences, see Table S2 in the supplemental material]), covering the
raaS upstream region, were used in binding experiments with RaaS. (C) 32P-labeled annealed oligonucleotides (20 nM) were mixed with 170 nM purified RaaS.
WT is Pr14 (GGGATGAACGTACGTTTAATATCCTGAACATGCGTTCAG); M6 is a single-repeat oligonucleotide (GGGTGAACATGCGTTCA), and the
mutated double-repeat oligonucleotide is M5 (GGGATGAACGTACGAAAAATATCCTGAACATGCGTTCAG). In the M5 oligonucleotide, 3 thymidines were
replaced with adenosines (underlined) to interfere with possible DNA secondary structures. (D) Anisotropy binding profile for interaction of Atto647N-DNA (4
nM) with RaaS.
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(raaSMtb) decreased with incubation time (in drug-free me-
dium) compared to the wild-type and raaSMtb-complemented
(raaSMtb com) strains, with approximately 20 times fewer viable
raaSMtb bacteria than the wild type after 7 months of culture
(Fig. 5A). Complementation of themutant fully restored thewild-
type phenotype (Fig. 5A). Loss of RaaS function also impactedM.
tuberculosis intercellular survival. At anMOI of 5,raaSMtb bacilli
were able to multiply similarly to the wild type in the human
macrophage Mono Mac 6 cell line in the first 72 h; however, sur-
vival was reduced in the late stages of infection (P 	 0.01), indi-
cating that RaaS plays an important role in long-term survival of
M. tuberculosis in macrophages (Fig. 5B). This survival defect was
abolished in the complementedmutant. At a lowerMOI (0.1), the
raaSMtb strain was not able to replicate in macrophages, in con-
trast to the wild type (Fig. 5C), while complementation of the
mutant restored the wild-type phenotype. Our results confirmed
that RaaS is required for successful persistence ofM. tuberculosis in
vitro and in macrophages. Additionally, we established that raaS
was 3.65-fold (0.16-fold) overexpressed inM. tuberculosis com-
pared toM. bovis BCG, suggesting that downregulation of raaS in
the latter species may contribute to its impaired survival in sta-
tionary phase.
DISCUSSION
There is an increasing understanding of the complexity of bacte-
rial physiological processes that, as in eukaryotic cells, are influ-
enced by periods of nongrowth, senescence, and death. Here we
have proposed a molecular mechanism for regulating efflux that
contributes to mycobacterial survival under nonpermissive
growth conditions. We first presented data showing thatM. bovis
BCGhas a general survival defect under nonreplicating conditions
(Fig. 1A), which was significantly improved on administration of
several antimicrobial compounds targeting cell wall biosynthesis
(Fig. 1B). We identified a transcriptional regulator (Rv1219c,
named RaaS in this study) that was strongly induced by the anti-
microbial treatment and mediated expression of the putative
ATP-dependent efflux pump encoded by bcg1278c/bcg1277c
(rv1218c/rv1217c). Whereas overexpression of raaS from two dif-
ferent plasmid systemsmimicked the survival-promoting effect of
ethambutol, raaS deletion substantially reduced the ethambutol
effect on mycobacterial survival. However, it did not abolish the
ethambutol effect completely, indicating that other factors might
be involved in the regulation of this pathway. Indeed, ChIP-
seq data maps (available at the TB Database [http://genome.tbdb
.org/]) show the binding of at least two additional transcription
FIG 5 RaaS is important for persistence ofM. tuberculosis in prolonged stationary phase and in human macrophages. (A) Wild-type, raaSMtb, and raaSMtb
com strains were incubated in 7H9medium without shaking at 37°C for 7 months. **, raaSMtb had a significant survival defect (P	 0.01; n
 3) compared to
the wild-type or raaSMtb com strains after 135 and 210 days of incubation. (B and C) MonoMac 6 cells were infected with wild-type, raaSMtb, and raaSMtb
com strain cells at anMOI of 5 (B) or 0.1 (C). TheraaSMtb strain had a significant survival defect (P	 0.01; n
 3) compared to the wild-type orraaSMtb com
strain after 96 and 144 h.
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factors (Rv0880 and Rv2779c) to the RaaS operon that may par-
tially compensate for the loss of RaaS under certain conditions.
Nevertheless, our data on overexpression of raaS inM. bovis BCG
strongly support the proposed role of RaaS as amajor regulator of
metabolite-regulated shutdown of efflux and consequent im-
provement of mycobacterial survival. Why does downregulation
of efflux stimulate mycobacterial survival? It has been proposed
that efflux pumps are involved in general cellular detoxification,
and therefore they could be important in nonreplicating persis-
tence (37).We argue, however, that the toxic by-products of active
metabolismmight be reduced in conditions of low nutrient avail-
ability. Indeed, reduced membrane transport processes and low
metabolic activity are considered important characteristics of
nongrowing persistent bacteria (10, 38, 39). Therefore, shutdown
of efflux to minimize the use of ATP and the loss of potential
metabolites would be beneficial for nongrowing bacteria, but it
would require complex regulatory cascades to control these pro-
cesses. Although we do not yet know precisely how exposure to
antimicrobial compounds triggers RaaS-mediated shutdown of
the Rv1218c-Rv1217c efflux pump, our findings suggest that
ATP-dependent pumps are an important part of the metabolic
circuitry and energy metabolism of growing cells, as their activity
depends on the metabolic state of the bacterium and is finely
tuned by metabolites binding to transcriptional regulators. We
hypothesize that RaaS expression is regulated by metabolites pro-
duced during active growth. Under stressful conditions (for ex-
ample, hypoxia or iron limitation), mycobacteria slow their me-
tabolism and redirectmetabolic fluxes from the tricarboxylic cycle
to alternative pathways and to the synthesis of storage compounds
(40, 41). In stressful conditions, free RaaS binds to its DNA rec-
ognition sequence, repressing the transcription of this cluster of
efflux pump genes and also itself, in a classical feedback loop. We
propose that antimicrobial treatment potentiates this process, di-
rectly or indirectly influencing levels of the putative RaaS ligand.
The presented results indicate that RaaS is a part of the complex
regulatorymechanisms that orchestrate a coordinated downregu-
lation of energy-consuming processes and the activation of long-
termpersistence. This hypothesis is supported by our findings that
M. tuberculosis employs the RaaS-mediated mechanism for in
vitro persistence during in vivomacrophage infection and in pro-
longed stationary phase (Fig. 5A to C). Our results on raaS up-
regulation in M. tuberculosis indicate that this RaaS-mediated
mechanism is partially disabled in M. bovis BCG compared with
M. tuberculosis, which contributes to the failure ofM. bovisBCG to
persist in growth nonpermissive conditions. Overexpression of
rv1219c inM. bovis BCG overcomes this defect.
Our results led us to two clinically relevant conclusions. Un-
controlled expression of a single ABC transporter can impair the
viability of nonreplicating mycobacteria and therefore may be
used as a strategy to kill them. An argument against this therapeu-
tic approach is that excessive expression of an efflux pump may
result in multiple-drug resistance of mycobacteria. However, al-
teration of Rv1218c efflux pump expression does not influence
sensitivity to frontline antimicrobials (42). Therefore, dysregula-
tion of this efflux system by using low-molecular-weight com-
pounds to disrupt theDNA-binding activity of RaaS, analogous to
inhibition of the transcriptional regulator EthR (43),might offer a
novel opportunity to specifically target persistent M. tuberculosis
bacilli. Our results suggest that efflux pump inhibitors, which have
recently been recognized as a new rich source of drugs for the
prevention of multiple-drug resistance in replicating bacteria (8,
18), should be used with caution for the treatment of infections
associated with nonreplicating bacteria, as they may actually pro-
mote the long-term survival of the bacteria.
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